Esophageal cancer is one of the common malignant tumors with high incidence and poor prognosis. Angiogenesis-related pathways play an important role in the occurrence and development of esophageal cancer. Vascular endothelial growth factor (VEGF) is the main mediator of angiogenesis. In addition to promoting angiogenesis and maintaining the survival of neovascularization, VEGF can also directly act on esophageal cancer cells and promote the occurrence and development of tumors. This article reviews the biology of VEGF and its effect on blood vessels, the expression of VEGF in esophageal cancer cells and its influencing factors, the role of VEGF in esophageal cancer cells, the immunomodulatory activity of VEGF and the clinical study of VEGF inhibitors. The purpose of this study is to provide a basis for more rational use of VEGF inhibitors in the treatment of esophageal cancer.
The incidence of complications after radical resection of esophageal carcinoma is high up to about 20%-50%. The incidence of pneumonia, pleural effusion, tracheal intubation, anastomotic fistula and cardiac events is relatively high. Among them, pulmonary complications are the most common complications after esophageal cancer operation and cause the most perioperative deaths. Among the factors that influence the occurrence of postoperative complications of esophageal cancer, the amount of fluid infusion during and after the operation is closely related to the occurrence of postoperative complications. Moreover, in the environment of enhanced recovery after surgery (ERAS), it is more important to optimize the postoperative fluid management of esophageal cancer. Restricted fluid therapy plays a more and more important role in patients undergoing esophagectomy. This review integrated the relevant research results and discussed the advantages of the restricted fluid therapy compared with other fluid therapy, how to control the restricted infusion volume and infusion speed and how to monitor and evaluate the infusion process and the selection of infusion types, so as to provide reference for clinical practice test.
Immunotherapy is an important treatment method in tumor therapy. Among them, programmed death-1/programmed death ligand-1 inhibitors are the immune preparations with mature application and great survival benefit at present. Programmed death-1/programmed death ligand-1 inhibitors brought better clinical benefits to patients with esophageal cancer and provided more favorable choice for the treatment of esophageal cancer. This article introduces the mechanism of action, application in esophageal cancer, and efficacy predictors of programmed death protein-1/programmed death protein ligand-1 inhibitors, aiming to provide a theoretical basis for the more rational use of programmed death protein-1/programmed death protein ligand-1 inhibitors in patients with esophageal cancer.
ObjectiveTo explore Nursing Effect about patients' Accelerated Rehabilitation Surgery after Thoracoscopic Esophageal CarcinomaMethodsContinuous collection of 90 patients with thoracoscopic esophageal cancer from March 2017 to 2018 in this hospital, of which 45 patients in the control group were given routine care, and 45 patients in the experimental group were given individualized care. Analysis of nursing satisfaction and gastrointestinal function in two groups.ResultsThe satisfaction and gastrointestinal function of the two groups of patients were analyzed.. The average bowel sound recovery time and anal exhaust time were significantly shorter in the experimental group(31.25 ± 2.25 H, 50.12 ± 1.47 H) than in the control group(45.26 ± 2.17 H, 67.36 ± 1.06 H)(P = 0.028, P = 0.030). The incidence of adverse reactions was significantly lower in the experimental group(4.44 %) than in the control group(17.77 %)(P = 0.012), Nursing satisfaction was significantly higher in the experimental group(97.78 %) than in the control group(80%)(P = 0.007), Average hospitalization days and hospitalization costs in the experimental group(12.5±2.8d,9823±720￥),They were all significantly shorter than the control group16.3±3.4d,1378±790￥)(P =0.023, P =0.036）.ConclusionThe accelerated rehabilitation surgical care of patients with thoracoscopic esophageal cancer during perioperative period can help patients to accelerate recovery by promoting the recovery of gastrointestinal energy.
